Download pdf
Fexinidazole, A Promising Oral Treatment against Human African Trypanosomiasis, Clinical Research, and Potential
- 1 School of Chemistry, The University of Hong Kong, China
- 2 College of Liberal Arts and Sciences, University of Connecticut, United States of America
- 3 School of Parmacy, Wenzhou Medical University, Wenzhou, China
* Author to whom correspondence should be addressed.
Abstract
HAT, a parasitic disease that has significant impact on human nervous system, has caused several epidemic in sub-Sahara area. Between 1960-1990, approximately 5 HAT epidemic broke out in these areas. HAT can be aggressively communicable and vital without any treatment with a death rate of 95%. In addition, only little symptoms showed after infection so many patients who are not conscious about it may cause even more severe epidemic. In recent years, roughly 300 patients still die for it yearly. To cope with the disease, several medical companies make efforts to seek for treatments effectively against HAT. These research on treatment can prevent the wide spread of HAT and help patients to come back to their normal lives. The life expectancy and quality will also improve with treatment for HAT. Therefore, in this review, we collect information and data about HAT and relevant treatment. Among treatments, we focus on a recent drug named Fexinidazole, which can be effective to treat all phases of HAT. Furthermore, it also has potential to guide a new approach in finding new drugs by research on its mechanism.
Keywords
HAT, HAT treatment, fexinidazole, Human African Trypanosomiasis
[1]. WHO, 2022, Human African trypanosomiasis (sleeping sickness), HAT data and information from WHO website. https://www.who.int/news-room/fact-sheets/detail/trypanosomiasis-human-african-(sleeping-sickness)
[2]. Drugbank, 2022 April 06, Fexinidazole, https://go.drugbank.com/drugs/DB12265
[3]. Victor Kande Betu Ku Mesu, DPH, Wilfried Mutombo Kalonji, MD, [...], and Antoine Tarral, MD, 2021 Jun 15, Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220131/
[4]. Wikipedia, 2022 August, Human African Trypanomiasis, HAT data and information from wikipedia
[5]. Pixelsquid, 2022 Feb 12, AfrTryp LifeCycle, By Pixelsquid - This file was derived from:AfrTryp LifeCycle.png by Јованвб2005 Surface Anatomy of the Heart.jpg by OpenStax CollegeTsetsemeyers1880.jpgUnited States Centers for Disease Control and Prevention logo.svg by United States Centers for Disease Control and Prevention, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=101297671
[6]. Bahia MT, Mayer de Andrade I, Fontes Martins TA, da Silva do Nascimento AF, de Figueiredo Diniz L, Santana Caldas I, Talvani A, Bourdin Trunz B, Torreele E, Ribeiro I, PLoS Negl Trop Dis, November 2012, Fexinidazole: A potential new drug candidate for Chagas disease, Fexinidazole information from DNDi
[7]. MFMER , 2021, Drugs and Supplements Fexinidazole (Oral Route), Fexinidazole (Oral Route) Side Effects - Mayo Clinic
Cite this article
Huang,J.;Liu,L.;Wang,J. (2023). Fexinidazole, A Promising Oral Treatment against Human African Trypanosomiasis, Clinical Research, and Potential. Theoretical and Natural Science,3,482-486.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 2nd International Conference on Biological Engineering and Medical Science (ICBioMed 2022), Part I
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).